Medtronic Inc. (MDT) recently launched a new TSRH 3Dx Spinal System, which is a hook, rod and screw system used in complex spinal procedures. The system offers two screws designed to address multiple pathologies. The Multi Planar Adjusting (MPA) Screw gives surgeons the flexibility of a variable angle posted screw for targeted, controlled correction maneuvers. The OSTEOGRIP Screw enhances bone fixation by incorporating a dual-lead thread pattern that reduces toggle at the bone-screw interface.
The new pedicle screw system has a unique technology that addresses multiple spinal pathologies, from degenerative disc disease to spinal deformity. The product offers an alternative to patients for spinal stabilization with fusion. It works for patients suffering from degenerative spinal conditions, deformity, or injury of the thoracic, lumbar, and sacral spine. The TSRH Spinal System also provides Chromaloy rods and a minimally invasive capability.
We think that the new product will be widely accepted by orthopedic surgeons as a result of its unique features. This will expand Medtronic’s revenues in the Spinal and Biologics segment.
Medtronic is one of the world’s leading medical technology companies, specializing in implantable and interventional therapy devices and products. The company’s main competitors include St. Jude Medical (STJ) and Boston Scientific Corporation (BSX).
Medtronic’s management has a typical “ONE Medtronic" approach that encompasses the following goals: drive sustainable long-term growth of 9%−11% through innovation, focus on operating margins − increase by 300 to 400 basis points, EPS growth of 11%−14% and return a minimum of 40%−50% of free cash flow to shareholders annually, and align the organization for consistent execution. Medtronic’s fiscal first quarter results indicate that the company is well on track to achieve these goals.
Read the full analyst report on "MDT"Read the full analyst report on "STJ"Read the full analyst report on "BSX"Zacks Investment Research
